Next report date
Report period
Q1 2024
EPS estimate
−0.02EUR
Revenue estimate
9.84 MEUR
5596.145
0.000EUR
23.75 KEUR
44.53 MEUR
26.22 M
About PHOTOCURE ASA
Sector
Industry
CEO
Daniel Schneider
Website
Headquarters
Oslo
Founded
1993
ISIN
NO0010000045
FIGI
BBG000BCZSJ0
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. Its products include Metvix for nonmelanoma skin cancer, Hexvix/Cysview for better detection and management of bladder cancer, and Cevira which is a photodynamic drug-device combination product for non-surgical treatment of high-grade cervical dysplasia. The company operates through the Commercial Franchise and Development Portfolio segments. The Commercial Franchise segment includes the sale of Hexvix/Cysview in the U.S. and Europe and other sales from partners and other products. The Development Portfolio segment focuses on the development of pipeline products. The company was founded in 1997 and is headquartered in Oslo, Norway.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange PHOTOCURE ASA NK-,50 stocks are traded under the ticker PHS.
PHOTOCURE ASA NK-,50 is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
PHS earnings for the last quarter are −0.02 EUR per share, whereas the estimation was −0.04 EUR resulting in a 58.77% surprise. The estimated earnings for the next quarter are −0.01 EUR per share. See more details about PHOTOCURE ASA NK-,50 earnings.
PHOTOCURE ASA NK-,50 revenue for the last quarter amounts to 9.50 M EUR despite the estimated figure of 9.85 M EUR. In the next quarter revenue is expected to reach 11.35 M EUR.
Yes, you can track PHOTOCURE ASA NK-,50 financials in yearly and quarterly reports right on TradingView.
PHS net income for the last quarter is 1.11 M EUR, while the quarter before that showed −423.14 K EUR of net income which accounts for 362.26% change. Track more PHOTOCURE ASA NK-,50 financial stats to get the full picture.
No, PHS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PHS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHOTOCURE ASA NK-,50 stock right from TradingView charts — choose your broker and connect to your account.
We've gathered analysts' opinions on PHOTOCURE ASA NK-,50 future price: according to them, PHS price has a max estimate of 7.65 EUR and a min estimate of 7.47 EUR. Watch PHS chart and read a more detailed PHOTOCURE ASA NK-,50 stock forecast: see what analysts think of PHOTOCURE ASA NK-,50 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHOTOCURE ASA NK-,50 EBITDA is 13.57 M EUR, and current EBITDA margin is 30.48%. See more stats in PHOTOCURE ASA NK-,50 financial statements.